Lupin has received FDA approval for four strengths of generic Lotrel (amlodipine and benazepril combination). Lotrel, a Novartis product, is protected by one OB listed patent – ‘802, expiry in Dec’17. At that time, the Lotrel market size was roughly $1.4 bln.
Generic Lotrel is clearly a lucrative product for Lupin, where the upside will depend on the timing of launches by other players. For Lupin Labs, Morgan Analyst assumes $40 mln sales for Lupin in F11 (based on a five (more…)